undamentalytics Newsletter
Sign in

Neuphoria Therapeutics Inc. cash flow statement

In fiscal 2026, Neuphoria Therapeutics Inc.'s operations generated −$12.4m of cash.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2025Jun 20252026Jun 2026
Cash from operations0−12
Depreciation and amortisation11
Stock-based pay00
Shares issued218

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Neuphoria Therapeutics Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Neuphoria Therapeutics Inc.